botulinum toxin type A

onabotulinumtoxinA

An injectable formulation of a neurotoxin derived through the fermentation of the Hall strain of Clostridium botulinum type A with neuromuscular transmission inhibitory and analgesic activities. Upon injection into the affected muscle, the heavy chain portion of onabotulinumtoxinA binds to the cell membrane of the motor nerve and is internalized via endocytosis. Upon entry, the light chain portion of the toxin is activated and cleaves the protein SNAP-25, thereby preventing the fusion of acetylcholine (ACh)-containing synaptic vesicles with the cell membrane and, so, the releaseof ACh into the neuromuscularjunction; subsequent binding of ACH to motor end-plate nicotinic acid receptors and ACh-mediated muscle contraction are thus blocked. In addition to ACh, onabotulinumtoxinA may inhibit the release of neuropeptides, such as substance P and glutamate, which may contribute to its analgesic activity. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C82623" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C82623" NCI Thesaurus)

http://purl.bioontology.org/ontology/PDQ/CDR0000634923

onabotulinumtoxinA

abobotulinumtoxinA

onaclostox

botulinum neurotoxin type A

botulinum toxin A

botulinum A toxin

Dysport

BOTOX

Botox cosmetic

BTX-A

C0006050

C2719767

C0700702

C0591427

C1633696

C2719424

C4083128

2009-02-09

2011-11-01

An injectable formulation of a neurotoxin derived through the fermentation of the Hall strain of Clostridium botulinum type A with neuromuscular transmission inhibitory and analgesic activities. Upon injection into the affected muscle, the heavy chain portion of onabotulinumtoxinA binds to the cell membrane of the motor nerve and is internalized via endocytosis. Upon entry, the light chain portion of the toxin is activated and cleaves the protein SNAP-25, thereby preventing the fusion of acetylcholine (ACh)-containing synaptic vesicles with the cell membrane and, so, the releaseof ACh into the neuromuscularjunction; subsequent binding of ACH to motor end-plate nicotinic acid receptors and ACh-mediated muscle contraction are thus blocked. In addition to ACh, onabotulinumtoxinA may inhibit the release of neuropeptides, such as substance P and glutamate, which may contribute to its analgesic activity. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C82623" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C82623" NCI Thesaurus)

TRD

C82623

CDR0000634923

Drug/agent

botulinum toxin type A

T109

T116

T131

T129

T121